Superworth

Cytokinetics price to book ratio CYTK

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
56.2×
Nov 2024
10-year median
9.1×
10-year range
2.8× to 193×
Peer median
9.2×

Cytokinetics' price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Nov 2024, at 56.2×.

On the days it had one over the last ten years, its median was 9.1×, from 2.8× in Nov 2017 to 193× in Jun 2019.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
202456.2×55.6×62.1×
2023n/m a value too high to mean anything
202231.9×10.2×46.1×
202115.4×8.9×193×
20209.8×7.6×10.0×
2019191×7.2×193×
20186.4×2.9×8.3×
20173.0×2.8×7.3×
20165.8×3.6×10.0×
20156.0×2.4×6.9×
20143.1×1.4×7.6×
20135.0×1.4×6.5×
20121.2×1.0×1.9×
20111.2×1.1×1.5×

Against its peers

Companies in Drug Manufacturers - General nearest Cytokinetics' size, closest first, today.

CompanyPrice to book ratio
CYTKCytokineticsn/m
TGTXTG Therapeutics13.7×
PTGXProtagonist Therapeutics10.6×
CORTCorcept Therapeutics13.2×
ALKSAlkermes plc.4.0×
BMRNBiomarin Pharmaceutical1.7×
AMRXAmneal Pharmaceuticals197×
LGNDLigand Pharmaceuticals6.3×
KNSAKiniksa Pharmaceuticals International9.2×
JAZZJazz Pharmaceuticals2.9×
INDVIndivior Pharmaceuticalsn/m
Peer median9.2×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Cytokinetics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.